http://met-tech.com/fractured-input-shaft.html
Life sciences and technology investor Safeguard said the gain and an increase in shareholders’ equity will be recognized in the currenr quarter ending June 30. A private placement with reduced Safeguard’s share in Clarientg (NASDAQ:CLRT) from about 50 percent to about 47 Safeguard President and CEOPeter J. Boni said the deal “nort only strengthened our balance sheet andfinancialk flexibility, but the value of Safeguard’sd ongoing stake in Clarient can now be more readily understood by the investment community.” Safeguardf said the market value of its remaining holdingsx is about $123 million as of Wednesday.
Clarient providees anatomic pathology and molecular testing servicedsto pathologists, oncologists and the pharmaceutical It’s based in Aliso Viejo, Calif.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment